BIORESTORATIVE THERAPIES INC. - COMMON STOCK

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

27 Feb 2025 09:45:00 By Nasdaq GlobeNewswire

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

26 Feb 2025 20:15:00 By Nasdaq GlobeNewswire

BioRestorative to Provide a Positive FDA Update on Clinical Pipeline

25 Feb 2025 08:00:01 By Nasdaq GlobeNewswire

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

20 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

BRTX-100 Front and Center at ORS 2025

10 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

05 Dec 2024 06:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

05 Nov 2024 07:10:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

10 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

03 Oct 2024 16:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

19 Sep 2024 06:55:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update

13 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024

06 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

23 Jul 2024 07:10:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

27 Jun 2024 07:40:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

17 Jun 2024 07:05:00 By Nasdaq GlobeNewswire

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

13 Jun 2024 07:00:00 By Nasdaq GlobeNewswire